Development code · Small Molecule
CVL-231
CVL-231 is a development code for Emraclidine (CVL-231), developed by Cerevel Therapeutics Holdings, Inc..
- Status
- Phase 2 for Schizophrenia
- Mechanism
- M4 PAM
- Developer
- Cerevel Therapeutics Holdings, Inc.
Programs
- Emraclidine (CVL-231) for SchizophreniaPhase 2Active
Also known as
- PF-06852231
- emraclidine
- 2170722-84-4